BR9708082A - Compostos e métodos para a imunoterapia e imunodiagnose de câncer de próstata - Google Patents

Compostos e métodos para a imunoterapia e imunodiagnose de câncer de próstata

Info

Publication number
BR9708082A
BR9708082A BR9708082A BR9708082A BR9708082A BR 9708082 A BR9708082 A BR 9708082A BR 9708082 A BR9708082 A BR 9708082A BR 9708082 A BR9708082 A BR 9708082A BR 9708082 A BR9708082 A BR 9708082A
Authority
BR
Brazil
Prior art keywords
immunodiagnosis
immunotherapy
compounds
methods
prostate cancer
Prior art date
Application number
BR9708082A
Other languages
English (en)
Inventor
Steven G Reed
Davin C Dillon
Daniel R Twardzik
Original Assignee
Corixa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corixa Corp filed Critical Corixa Corp
Publication of BR9708082A publication Critical patent/BR9708082A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
BR9708082A 1996-03-15 1997-03-14 Compostos e métodos para a imunoterapia e imunodiagnose de câncer de próstata BR9708082A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61674596A 1996-03-15 1996-03-15
US63384096A 1996-04-11 1996-04-11
PCT/US1997/004192 WO1997033909A2 (en) 1996-03-15 1997-03-14 Compounds and methods for immunotherapy and immunodiagnosis of prostate cancer

Publications (1)

Publication Number Publication Date
BR9708082A true BR9708082A (pt) 1999-07-27

Family

ID=27087847

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9708082A BR9708082A (pt) 1996-03-15 1997-03-14 Compostos e métodos para a imunoterapia e imunodiagnose de câncer de próstata

Country Status (11)

Country Link
US (1) US6034218A (pt)
EP (1) EP0914335A2 (pt)
KR (1) KR19990087802A (pt)
AR (1) AR006250A1 (pt)
AU (1) AU728186B2 (pt)
BR (1) BR9708082A (pt)
CA (1) CA2249742A1 (pt)
CO (1) CO4600637A1 (pt)
NO (1) NO984229L (pt)
NZ (1) NZ331866A (pt)
WO (1) WO1997033909A2 (pt)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6592877B1 (en) * 1995-09-01 2003-07-15 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6290969B1 (en) * 1995-09-01 2001-09-18 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6458366B1 (en) 1995-09-01 2002-10-01 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
SE520392C2 (sv) 1996-09-27 2003-07-01 Creative Peptides Sweden Ab C Specifika peptider för behandling av diabetes mellitus
US6630305B1 (en) 1999-11-12 2003-10-07 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US7202342B1 (en) 1999-11-12 2007-04-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
NZ337446A (en) 1997-02-25 2001-02-23 Corixa Corp Immunogenic portions of a prostate protein and their use in immunotherapy of prostate cancer and methods for their use
US6894146B1 (en) 1997-02-25 2005-05-17 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6943236B2 (en) 1997-02-25 2005-09-13 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6395278B1 (en) 1997-02-25 2002-05-28 Corixa Corporation Prostate specific fusion protein compositions
US7033827B2 (en) 1997-02-25 2006-04-25 Corixa Corporation Prostate-specific polynucleotide compositions
US6329505B1 (en) 1997-02-25 2001-12-11 Corixa Corporation Compositions and methods for therapy and diagnosis of prostate cancer
US6818751B1 (en) 1997-08-01 2004-11-16 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6620922B1 (en) 1997-02-25 2003-09-16 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US20030185830A1 (en) 1997-02-25 2003-10-02 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6800746B2 (en) 1997-02-25 2004-10-05 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US7517952B1 (en) 1997-02-25 2009-04-14 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6261562B1 (en) 1997-02-25 2001-07-17 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
US6759515B1 (en) 1997-02-25 2004-07-06 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6613872B1 (en) 1997-02-25 2003-09-02 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
US6465611B1 (en) 1997-02-25 2002-10-15 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
US6555653B2 (en) * 1997-05-20 2003-04-29 Corixa Corporation Compounds for diagnosis of tuberculosis and methods for their use
AU9689398A (en) * 1997-10-07 1999-04-27 Corixa Corporation Compounds and methods for immunotherapy and immunodiagnosis of prostate cancer
AU2474699A (en) * 1998-01-26 1999-08-09 Genquest Inc. Compositions and methods for detecting and treating prostate cancer
KR20010083111A (ko) * 1998-07-14 2001-08-31 길리스 스티브 전립선암의 치료 및 진단을 위한 조성물 및 방법
US6458925B1 (en) * 1998-08-03 2002-10-01 University Of Maryland, Baltimore Peptide antagonists of zonulin and methods for use of the same
US6387888B1 (en) 1998-09-30 2002-05-14 American Foundation For Biological Research, Inc. Immunotherapy of cancer through expression of truncated tumor or tumor-associated antigen
GB9828840D0 (en) * 1998-12-30 1999-02-17 Univ Nottingham Trent Prostate cancer associated genes and their products
US8143386B2 (en) * 1999-04-07 2012-03-27 Corixa Corporation Fusion proteins of mycobacterium tuberculosis antigens and their uses
AU5173400A (en) * 1999-05-28 2000-12-18 Sugen, Inc. Protein kinases
MXPA01001885A (es) * 1999-06-21 2002-04-24 Inkine Pharmaceutical Company Angiocidina: un receptor de adhesion a celula tumoral especifico de cys-ser-val-thr-cys-gly.
US20020058292A1 (en) * 2000-12-08 2002-05-16 Dillon Davin C. Ovarian tumor antigen and methods of use therefor
WO2001024820A1 (en) * 1999-10-07 2001-04-12 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
AU1656501A (en) * 1999-11-12 2001-06-06 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
EP1261708A2 (en) * 2000-01-14 2002-12-04 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
WO2001062893A2 (en) 2000-02-25 2001-08-30 Corixa Corporation Compounds and methods for diagnosis and immunotherapy of tuberculosis
WO2001081403A1 (en) * 2000-04-26 2001-11-01 The Scripps Research Institute Pancreatic progenitor 1 gene and its uses
ATE526994T1 (de) * 2000-06-20 2011-10-15 Corixa Corp Mtb32a antigen aus mycobakterium tuberculosis mit inaktivierter protease aktivität und fusionsproteine die das antigen enthalten
WO2002006330A2 (en) * 2000-07-18 2002-01-24 Millennium Pharmaceuticals, Inc. 13237,18480,2245 or 16228 human protein kinase molecules and uses therefor
AU2001279082A1 (en) * 2000-07-31 2002-02-13 Gene Logic, Inc. Expression of gage/page-like protein in benign prostatic hyperplasia
US7048931B1 (en) 2000-11-09 2006-05-23 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
MXPA03004579A (es) * 2000-11-28 2003-09-04 Wyeth Corp Analisis de expresion de acidos nucleicos del regulador de cromatina dependiente de actina y polipeptidos utiles en diagnostico y tratamiento del cancer de prostata.
US6821731B2 (en) 2000-11-28 2004-11-23 Wyeth Expression analysis of FKBP nucleic acids and polypeptides useful in the diagnosis of prostate cancer
EP1343912A2 (en) 2000-11-28 2003-09-17 Wyeth Expression analysis of kiaa nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
CA2439442A1 (en) * 2001-02-26 2002-09-06 Xianghe Yan Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof
WO2002069907A2 (en) * 2001-03-07 2002-09-12 Mannkind Corporation Anti-neovasculature preparations for cancer
US20030118585A1 (en) * 2001-10-17 2003-06-26 Agy Therapeutics Use of protein biomolecular targets in the treatment and visualization of brain tumors
WO2003000727A2 (en) 2001-06-21 2003-01-03 Isis Innovation Limited Atopy
WO2003008582A1 (en) * 2001-07-19 2003-01-30 The New Industry Research Organization Novel human-origin protein binding to sphingosine kinase 1 and polynucleotide encoding the protein
US8507445B2 (en) * 2001-09-07 2013-08-13 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
AU2003213118A1 (en) 2002-02-15 2003-09-09 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
DE10217254A1 (de) 2002-04-15 2003-10-23 Proteosys Ag Verwendung von Substanzen zur Behandlung von Tumoren
WO2006023598A2 (en) * 2004-08-19 2006-03-02 University Of Maryland, Baltimore Prostate-specific antigen-derived mhc class ii-restricted peptides and their use in vaccines to treat or prevent prostate cancer
AU2006291054B2 (en) 2005-09-12 2011-10-13 The Brigham And Women's Hospital, Inc. Recurrent gene fusions in prostate cancer
US9957569B2 (en) * 2005-09-12 2018-05-01 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
JP5398268B2 (ja) 2006-02-09 2014-01-29 アルバ セラピューティクス コーポレーション タイトジャンクション・エフェクター用製剤
AU2007284651B2 (en) * 2006-08-09 2014-03-20 Institute For Systems Biology Organ-specific proteins and methods of their use
US20090069247A1 (en) 2006-10-06 2009-03-12 Blake Paterson Use of tight junction antagonists to treat inflammatory bowel disease
US8034776B2 (en) 2006-10-26 2011-10-11 Alba Therapeutics Corporation Materials and methods for the treatment of celiac disease
AU2007317306B2 (en) * 2006-11-08 2012-06-14 The Regents Of The University Of Michigan SPINK1 as a prostate cancer marker and uses thereof
US9962424B2 (en) * 2007-04-27 2018-05-08 Lantmännen As-Faktor Ab Use of antisecretory factors (AF) for optimizing cellular uptake
AU2008275303B2 (en) 2007-07-06 2012-05-03 The Regents Of The University Of Michigan MIPOL1-ETV1 gene rearrangements
EP3018216B1 (en) 2007-07-06 2018-09-12 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
EP2597464B1 (en) 2007-08-16 2015-02-25 The Regents of the University of Michigan Metabolomic profiling of prostate cancer
AU2009253675A1 (en) 2008-05-28 2009-12-03 Genomedx Biosciences, Inc. Systems and methods for expression-based discrimination of distinct clinical disease states in prostate cancer
KR20110111474A (ko) 2009-01-09 2011-10-11 더 리젠츠 오브 더 유니버시티 오브 미시간 암에서의 반복적 유전자 융합체
US20100311815A1 (en) * 2009-02-23 2010-12-09 The Regents Of The University Of Michigan Mir-101 cancer markers
CA2774349C (en) 2009-09-17 2019-03-19 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
AU2011329753B2 (en) 2010-11-19 2015-07-23 The Regents Of The University Of Michigan ncRNA and uses thereof
US8945556B2 (en) 2010-11-19 2015-02-03 The Regents Of The University Of Michigan RAF gene fusions
DK3435084T3 (da) 2012-08-16 2023-05-30 Mayo Found Medical Education & Res Prostatakræftprognose under anvendelse af biomarkører
JP2018504595A (ja) 2015-01-05 2018-02-15 ユニバーシティ オブ オスロＵｎｉｖｅｒｓｉｔｙ ｏｆ Ｏｓｌｏ 前立腺癌マーカー及びその利用
WO2018039490A1 (en) 2016-08-24 2018-03-01 Genomedx Biosciences, Inc. Use of genomic signatures to predict responsiveness of patients with prostate cancer to post-operative radiation therapy
EP3571322B9 (en) 2017-01-20 2023-10-04 VERACYTE SD, Inc. Molecular subtyping, prognosis, and treatment of bladder cancer
CA3055925A1 (en) 2017-03-09 2018-09-13 Decipher Biosciences, Inc. Subtyping prostate cancer to predict response to hormone therapy
CA3062716A1 (en) 2017-05-12 2018-11-15 Decipher Biosciences, Inc. Genetic signatures to predict prostate cancer metastasis and identify tumor agressiveness

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990009446A1 (en) * 1989-02-17 1990-08-23 Plant Genetic Systems N.V. Cutinase
ES2276390T3 (es) * 1992-11-05 2007-06-16 Sloan-Kettering Institute For Cancer Research Antigeno de membrana especifico de la prostata.
ATE303160T1 (de) * 1993-08-11 2005-09-15 Jenner Technologies Impfstoff gegen prostatakrebs

Also Published As

Publication number Publication date
CA2249742A1 (en) 1997-09-18
CO4600637A1 (es) 1998-05-08
EP0914335A2 (en) 1999-05-12
WO1997033909A2 (en) 1997-09-18
US6034218A (en) 2000-03-07
WO1997033909A3 (en) 1997-12-24
AR006250A1 (es) 1999-08-11
AU2329597A (en) 1997-10-01
KR19990087802A (ko) 1999-12-27
AU728186B2 (en) 2001-01-04
NO984229L (no) 1998-11-13
NO984229D0 (no) 1998-09-14
NZ331866A (en) 2000-05-26

Similar Documents

Publication Publication Date Title
BR9708082A (pt) Compostos e métodos para a imunoterapia e imunodiagnose de câncer de próstata
IL131539A0 (en) Compounds for immunodiagnosis of prostate cancer and methods for their use
NO994069L (no) Forbindelser for immunoterapi av prostatacancer og fremgangsmate for anvendelse derav
DK1516629T3 (da) Humaniseret anti-CD-11a antibodies
BR9801538A (pt) Designação de transceptores flutuantes para radiocelular
EE9800348A (et) Raadiotelefoni elektromagnetiline varje
IL145800A0 (en) Immunotheraphy of cancer through expression of truncated tumor of tumor-associated antigen
DK0781136T3 (da) Forbindelser og fremgangsmåder til behandling af cancer
NO973064D0 (no) Anordning for komplettering av underjordisk brönn
DK0942754T3 (da) Konjugater anvendelige til behandlingen af prostatacancer
DK0934280T3 (da) PDE-IV-inhiberende 2-cyaniminoimidazolderivater
BR9708638A (pt) Processos de retardamento de desenvolvimento de tumores associados a cea usando-se anticorpos anti-idiotipo 3h1
IS5035A (is) Aðferðir til varnar gegn brjóstakrabbameini
AU9689398A (en) Compounds and methods for immunotherapy and immunodiagnosis of prostate cancer
BR9608702A (pt) Método para diagnosticar o câncer de próstata
NZ501742A (en) Methods of delaying development of HMFG-associated tumors using anti-idiotype antibody 11D10
IDP000008233A (id) Metode pencegahan kanker payudara
DE69707726T2 (de) Auskleidung
FI970717A0 (fi) Menetelmät kohtusyövän inhiboimiseksi
ZA972238B (en) Compounds and methods for immunotherapy and immunodiagnosis of prostate cancer.
ZA981536B (en) Compounds for immunodiagnosis of prostate cancer and methods for their use
ZA951113B (en) Tumor assosiated monoclonal antibody 123av16
ZA981585B (en) Compounds for immunotherapy of prostate cancer and methods for their use
AU6536898A (en) Compounds for immunodiagnosis of prostate cancer and methods for their use
DE59607778D1 (de) Tunnelauskleidung

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]